Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREATE: CAB LA + RPV LA in Pregnant and Postpartum Women With HIV
NCT07637942Phase 4Recruiting
- Sponsor
- IMPAACT Network
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 4, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by IMPAACT Network. Primary endpoints: Population Pharmacokinetics: Geometric Mean Clearance and Geometric Mean Pharmacokinetic Trough. Started Oct 2026; status: recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07637942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637942.